Topical corticosteroids, structure-activity and the glucocorticoid receptor: Discovery and development - A process of planned serendipity

Journal of Pharmaceutical Sciences

Volumn 97, Issue 8, 2008, Pages 2936-2947

  Katz, Martin ^a   Gans, Eugene H ^b,c  

^a Synymed Inc   (United States)

^b Hastings Senior Associates LLC   (United States)

^c Hastings Senior Associates LLC   (United States)

Author keywords

In vitro in vivo correlations (IVIVC); Receptors; Structure activity relationship (SAR); Synthesis; Transdermal

Indexed keywords

BETAMETHASONE VALERATE; CARBON 11; CLOBETASOL; CORTICOSTEROID DERIVATIVE; CORTICOSTERONE; CORTISONE; DESONIDE; DEXAMETHASONE; FLUDROCORTISONE; FLUDROXYCORTIDE; FLUMETASONE; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; PARAMETHASONE; PREDNISOLONE; PREDNISONE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ANTIINFLAMMATORY ACTIVITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INHIBITION; DRUG POTENCY; DRUG RELEASE; DRUG SOLUBILITY; FIBROBLAST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; VASOCONSTRICTION;

EID: 52449102677     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21222     Document Type: Review

References (55)

1. Fieser L, Fieser M. 1950. Steroids. New York: Reinhold Publishing Co.
2. Syntex: A corporation and a molecule: The Story of Research at Syntex. 1966. Palo Alto, CA: National Press.
3. Kendall EC. 1971. Cortisone. New York: Charles Scribner & Sons. pp. 121-137.
4. Birch AJ. 1995. To see the obvious. Profiles, pathways and dreams. Washington DC: American Chemical Society, series editor, Seeman, JI.
5. Murray JR. 1989. The history of corticosteroids. Acta Derm Venereol Suppl (Stockh) 151:4-6.
6. Hench PS, Kendall EC, Slocumb CH, Polley HF. 1949. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: Compound E) and the pituitary adrenocorticotropic hormone on rheumatoid arthritis. Preliminary report. Proc Staff Meetings Mayo Clinic 24:181-197.
7. Hench PS, Kendall EC, Slocumb CH, Polley HF. 1950. Cortisone, its effects on rheumatoid arthritis, rheumatic fever, and certain other conditions. Merck Rep 59:9-14.
8. Djerassi C. 1992. The pill, pygmy chimps, and Degas' horse. New York: Basic Books, pp. 34-48.
9. Murphy WB. 1994. Science and serendipity; A half century of innovation at Syntex. New York: Benjamin Co.
10. Rosenkranz G. Chemical Heritage Foundation Address, Philadelphia, 2005.
11. Wolff ME. 1979. Structure-activity relationships in glucocorticoids. Monogr Endocrinol 12:97-107.
12. Fried J, Thoma RW, Perlman D, Herz JE, Borman A. 1957. Recent Prog Horm Res 11:149.
13. β-ol-3-one with selenium dioxide. J Org Chem 21:239-240.
14. Herzog HL, Nobile A, Tolksdorf S, Charney W, Hershberg EB, Perlman PL. 1955. New antiarthritic steroids. Science 121:176.
15. Fried J, Borman A, Kessler WB, Grabowich P, Sabo EF. 1958. Cyclic 16α,17α-ketals and acetals of 9α-fluoro-16α-hydroxy- cortisol and -prednisolone. J Am Chem Soc 80:2338-2339.
16. Hogg JA, Spero GB, Thompson JL, Magerlein BJ, Schneider WP, Peterson DH, Sebek OK, Murray HC, Babcock JC, Pederson RL, Campbell JA. 1958. Chem Ind 1002.
17. Bowers A, Ringold HJ. 1958. Synthesis of halogenated steroid hormones - II, 6α- and 6β-fluorotestosterone and 6α- and 6β-fluoroprogesterone. Tetrahedron 3:14-27.
18. Bowers A, Ringold HJ. 1958. Steroids. CIII. A new class of potent cortical hormones, 6α-fluorocorticoids. J Am Chem Soc 80:4423-4424.
19. Edwards J. 1988. Modifications in the prednisone formula, fluorinated derivatives. 40th Anniversary Convocation of Discovery of Corticotherapy, Syntex, Mexico City.
20. Katz M, Poulsen BJ. 1972. Corticoid, vehicle, and skin interaction in percutaneous absorption. J Soc Cosmet Chem 25:565-590.
21. Lerner LJ, Turkheimer AR, Bianchi A, Singer FM, Borman A. 1964. Comparison of anti-granuloma, thymolytic and glucocorticoid activity of anti-inflammatory steroids. Proc Soc Exp Biol Med 16: 385-388.
22. Haleblian J. 1976. Bioassays used in development of topical dosage forms. J Pharm Sci 65:1425.
23. Sulzberger MB, Witten VH. 1952. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 19:101-102.
24. Maibach HI, Surber C, editors. 1992. Topical corticosteroids. Basel: Karger Publishers.
25. Counce JH, Brass A. 1972. Fluocinonide, a new topical corticosteroid for psoriasis and other dermatoses. J La State Med Soc 124:365-367.
26. Wieland P, Heer J, Schmidlin J, Miescher K. 1951. Über Steroide. 103. Mitteilung. Ester der Nebennierenrinden-Hormone mit protrahierter Wirkung. Helv Chim Acta 34:354-358.
27. Korting HC, Maibach HI, editors. 1993. Topical glucocorticoids with increased benefit/risk ratio, Vol. 21 of current problems in dermatology. Basel: Karger Publishers.
28. McKenzie AW, Stoughton RB. 1962. Method for comparing percutaneous absorption of steroids. Arch Dermatol 86:608-610.
29. Dumas KJ, Scholtz JR. 1972. The psoriasis bio-assay for topical corticosteroid activity. Acta Derm Venereol 52:43-48.
30. Barry BW. 1983. Dermatological formulations. New York: Marcel Dekker.
31. Place VA, Velazquez JG, Burdick KH. 1970. Precise evaluation of topically applied corticosteroid potency. Modification of the Stoughton-McKenzie assay. Arch Dermatol 101:531-537.
32. Katz M, Poulsen BJ. 1971. Absorption of drugs through the skin. In: Brodie B, Gillette J, editors. Handbook of experimental pharmacology, Vol. 28, Pt. 1. Berlin: Springer-Verlag. pp. 104-162.
33. Stoughton RB. 1972. Vasoconstrictor assay-specific applications. Topical corticosteroids. Basel: Karger Publishers. pp. 42-53.
34. Katz M, Shaikh ZI, Maibach HI. 2000. Scholtz-Dumas psoriasis small plaque bioassay. J Dermatolog Treat 11:15-19.
35. Katz M, Neiman HM. 1971. US Patent # 3,592,930, Moisture-deteriorable topical medicants, particularly anti-inflammatory steroids, in a substantially non-aqueous fatty alcohol-propylene glycol vehicle.
36. Shastri S, Shaikh ZI. 1977. US Patent # 4,017,615, Propylene carbonate ointment vehicle.
37. Scholtz JR. 1961. Topical therapy of psoriasis with fluocinolone acetonide. Arch Dermatol 84:1029-1030.
38. Katz M, Shaikh ZI. 1965. Percutaneous corticosteroid absorption correlated to partition coefficient. J Pharm Sci 54:591-594.
39. Gans EH, Wortzman MS. 2004. U.S. Patent # 6,765,001.
40. Stouch TR. 1992. Structure-activity relationships using multivariate analysis techniques: Application to topical corticosteroids. In: Maibach HI, editor. Topical corticosteroids. Basel: Karger Publishers. pp. 93-127.
41. Ponec M. 1984. Effects of glucocorticoids on cultured skin, fibroblasts and keratinocytes. Int J Dermatol 23:11-24.
42. Beger RD, Wilkes JG. 2001. Developing 13C NMR quantitative spectrometric data-activity relationship (QSDAR) models of steroid binding to the corticosteroid binding globulin. J Comput Aided Mol Des 15:659-669.
43. Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM. 1985. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 318:635-641.
44. Rhen T, Cidlowski JA. 2005. Anti-inflammatory action of glucocorticoids - New mechanisms for old drugs. N Engl J Med 353:1711-1723.
45. Ponec M. 1993. Glucocorticoid receptors. In: Korting HC, Maibach HI, editors. Topical glucocorticoids with increased benefit/risk ratio. Vol. 21 of current problems in dermatology. Basel: Karger Publishers. 24 p.
46. Zhou J, Cidlowski JA. 2005. The human glucocorticoid receptor: One gene, multiple proteins and diverse responses. Steroids 70:407-417.
47. Buchwald P, Bodor N. 2004. Soft glucocorticoid design: Structural elements and physiochemical parameters determining receptor-binding affinity. Pharmazie 59:396-404.
48. Beger RD, Buzatu DA, Wilkes JG, Lay JO Jr. 2001. (13)C NMR quantitative spectrometric data-activity relationship (QSDAR) models of steroids binding the aromatase enzyme. J Chem Inf Comput Sci 41:1360-1366.
49. Hammer S, Spika I, Sippl W, Jessen G, Kleuser B, Höltje HD, Schafer-Korting M. 2003. Glucocorticoid receptor interactions with glucocorticoids: Evaluation by molecular modeling and functional analysis of glucocorticoid receptor mutants. Steroids 68: 329-339.
50. Stahn C, Löwenberg M, Hommes DW, Buttgereit F. 2007. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol [Epub ahead of print].
51. Schacke H, Berger M, Rehwinkel H, Asadullah K. 2007. Selective glucocorticoid receptor agonists (SEGRAs): Novel ligands with an improved therapeutic index. Mol Cell Endocrinol [Epub ahead of print].
52. Song IH, Gold R, Straub RH, Burmester GR, Buttgereit F. 2005. New glucocorticoids on the horizon: Repress, don't activate. J Rheumatol 32:1199-1207.
53. Buttgereit F, Song IH, Straub RH, Burmester GR. 2005. Current insights into the development of new glucocorticoid receptor ligands. Z Rheumatol 64:170-176.
54. Einstein M, Greenlee M, Rouen G, Sitlani A, Santoro J, Wang C, Pandit S, Mazur P, Smalera I, Weaver AP, Zeng YY, Ge L, Kelly T, Paiva T, Geissler W, Mosley RT, Williamson J, Ali A, Balkovec J, Harris G. 2004. Selective glucocorticoid receptor nonsteroidal ligands completely antagonize the dexamethasone mediated induction of enzymes involved in gluconegenesis and glutamine metabolism. J Steroid Biochem Mol Biol 92:345-356.
55. Bledsoe RK, Stewart EL, Pearce KH. 2004. Structure and function of the glucocorticoid receptor ligand binding domain. Vitam Horm 68:49-91.